Q32 Bio Unveils Restructuring to Focus on Alopecia Areata Treatment; Shares Fall

MT Newswires Live
02-12

Q32 Bio (QTTB) shares were down Tuesday after the company said late Monday it was implementing a corporate restructuring to focus on advancing the bempikibart clinical development program for the treatment of alopecia areata.

The company is halting its phase 2 renal basket trial of ADX-097 and exploring strategic options for its tissue-targeted complement inhibitor platform, Q32 Bio said, adding that the restructuring, which includes workforce reductions, is projected to extend its cash runway until H2 of 2026.

Following positive results from the SIGNAL-AA part A trial, which showed Severity of Alopecia Tool score improvements and sustained response through week 55, the company said it plans to launch an open-label extension in H1 2025. The company also said it will begin dosing for SIGNAL-AA part B in H1, evaluating about 20 patients with severe AA over 36 weeks, with topline results expected in H1 of 2026.

Separately, Piper Sandler downgraded the company's stock to neutral from overweight, and cut its price target to $4 from $20.

Trading volume stood at around 594,000 shares against a daily average of 382,973.

Price: 2.77, Change: -0.41, Percent Change: -12.89

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10